SAN MATEO, Calif., Feb. 7 Anthera Pharmaceuticals, Inc., aprivately held biopharmaceutical company developing anti-inflammatory drugs,announced today that data from the Phase II trial of its novel secretoryphospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronaryheart disease will be presented as a late breaker at the 2008 American Collegeof Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 inChicago, Illinois.
The Phase II trial known as PLASMA (Phospholipase Levels And SerologicalMarkers of Atherosclerosis) was a multi-center, randomized, double-blind,placebo-controlled trial that enrolled approximately 400 patients with stablecoronary heart disease in the U.S. and Ukraine. Subjects were randomized toreceive one of four different doses of A-002 or placebo for up to eight weeks.Patients also received doctor-determined standard of care therapies. Theprimary endpoint was a reduction in secretory phospholipase A2 (sPLA2). Thestudy also evaluated the effect of Varespladib on cholesterol levels (LDL-C,non-HDL and total cholesterol) as well as inflammation in patients with stablecoronary heart disease.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held company committed todeveloping and commercializing clinical pharmaceutical products that addressunmet medical needs of patients with life-threatening, chronic and acuteinflammatory diseases and autoimmune disorders. The Company has acquired fromEli Lilly and Company and Shionogi & Co.? Ltd. worldwide rights (excludingJapan) to a series of clinical and pre-clinical compounds that inhibit theenzymatic activity of members of the phospholipase (PLA2) family -- a group ofenzymes responsible for the release of arachidonic acid and subsequentproduction of leukotrienes? prostacyclins and other mediators of inflammation.These highly potent compounds inhibit novel? upstream steps in theinflammation cascade and have the potential to address a variety of diseases.The company has also acquired exclusive and worldwide rights to a peptidefusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE)and other autoimmune diseases from Amgen. For more information, please visithttp://www.anthera.com.
Anne Bowdidge (650) 218-6900
email@example.comPLASMA Late-Breaker Trial Data Presentation: Date/Time: Monday, March 31 from 2:30-2:45pm. Title/Author: Effects of a Selective Inhibitor of Secretory Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways, Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical Atherosclerosis Research, Division of Cardiovascular Medicine at the University of Michigan, for the PLASMA Investigators. Location: McCormick Place, Vista Room S406
SOURCE Anthera Pharmaceuticals, Inc.